SCHEMBL21055086

SCHEMBL21055086

Cc1cccc(/C=N/Nc2cc3nc(C(=O)NC4CCNCC4)cn3c(N3CCOCC3)n2)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATR Q13535 1/20 0.49
PIKFYVE Q9Y2I7 10/20 0.49
KDM4E B2RXH2 3/20 0.49
MAPT P10636 3/20 0.49
LMNA P02545 3/20 0.49
HPGD P15428 1/20 0.49
FES P07332 1/20 0.42
FER P16591 1/20 0.42
TYK2 P29597 1/20 0.42
FRK P42685 1/20 0.42
SYK P43405 1/20 0.42
CAMK1D Q8IU85 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.42
ALDH1A1 P00352 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
ATM Q13315 1/20 0.38
KHK P50053 1/20 0.38
AVPR1B P47901 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30312542 1.00 ATR (0.49) ATRPIKFYVEKDM4EMAPTLMNA
SCHEMBL21055071 0.96 PIKFYVE (0.51) ATRPIKFYVEKDM4EMAPTLMNA
SCHEMBL30312521 0.96 PIKFYVE (0.51) ATRPIKFYVEKDM4EMAPTLMNA
SCHEMBL21055507 0.95 ATR (0.52) ATRPIKFYVEKDM4EMAPTLMNA
SCHEMBL30312386 0.95 ATR (0.52) ATRPIKFYVEKDM4EMAPTLMNA
SCHEMBL21055102 0.94 KDM4E (0.51) ATRPIKFYVEKDM4EMAPTLMNA
SCHEMBL30312410 0.93 LMNA (0.51) ATRPIKFYVEKDM4EMAPTLMNA
SCHEMBL21135504 0.93 LMNA (0.51) ATRPIKFYVEKDM4EMAPTLMNA
SCHEMBL21055011 0.93 LMNA (0.51) ATRPIKFYVEKDM4EMAPTLMNA
SCHEMBL30312523 0.93 LMNA (0.51) ATRPIKFYVEKDM4EMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11603372-B2 Compounds and therapeutic uses thereof VIOGEN BIOSCIENCES, LLC (US) 2023-03-14 US claimed
US-20210122752-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF VIOGEN BIOSCIENCES, LLC 2021-04-29 US claimed
WO-2019113523-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF BAJJI ASHOK (US) 2019-06-13 WO claimed
US-20240016810-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS YUMANITY THERAPEUTICS, INC. 2024-01-18 US disclosed
US-11603372-B2 Compounds and therapeutic uses thereof VIOGEN BIOSCIENCES, LLC (US) 2023-03-14 US disclosed
US-20210122752-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF VIOGEN BIOSCIENCES, LLC 2021-04-29 US disclosed
US-20210122752-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF VIOGEN BIOSCIENCES, LLC 2021-04-29 US disclosed
WO-2019113523-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF BAJJI ASHOK (US) 2019-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240016810-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS TARDBP, PIKFYVE, FUS ATR 777/4885PIKFYVE 2/4885KDM4E 788/4885
US-11603372-B2 Compounds and therapeutic uses thereof IL15, IL17A, IL2 ATR 4805/4885PIKFYVE 944/4885KDM4E 3881/4885
US-20210122752-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF IL15, IL17A, IL2 ATR 4805/4885PIKFYVE 944/4885KDM4E 3881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.